Detalles de la búsqueda
1.
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Breast Cancer Res
; 22(1): 33, 2020 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32252811
2.
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).
Clin Cancer Res
; 27(12): 3443-3455, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33785482
3.
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.
Ther Adv Med Oncol
; 12: 1758835920970081, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33335565
4.
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series.
Mol Clin Oncol
; 12(5): 456-460, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32257203
5.
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors.
Front Oncol
; 8: 608, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30631751
Resultados
1 -
5
de 5
1
Próxima >
>>